Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen.

Endothelial cells release von Willebrand factor (vWf) either constitutively or by a regulated pathway. Based on various studies in vitro, we hypothesized that the stimulatory action of histamine on vWf release could also be induced in vivo and that it may be inhibited by endogenous production of nitric oxide (NO). Nine healthy subjects received placebo or one of two dosages of a primed constant infusion of the NO-synthase inhibitor N-monomethyl-L-arginine (L-NMMA) in a randomized, double-blind, three-way crossover trial. Histamine was coinfused for 15 minutes at 0.16 microg/kg/min after 30 minutes of pretreatment with either placebo or L-NMMA. Thirty minutes after either the low or the high L-NMMA dose was started, which caused, respectively, a 40% decrease and a 60% decrease in exhaled end expiratory NO level (p = 0.008), there was no increase in von Willebrand factor antigen (vWf-Ag) level (p > 0.05). Histamine caused an 11% (95% confidence interval (CI): 0.4% to 22%; p = 0.011) increase in vWf-Ag level at 125 minutes. After pretreatment with the low and the high L-NMMA doses, vWf-Ag level increased by 18% (Cl: 5% to 31%; p = 0.011) and by 29% (CI: 15% to 42%; p = 0.008), respectively. At 125 minutes, vWf-Ag level was significantly higher after either L-NMMA pretreatment when compared with the results after histamine alone (p < 0.05). In conclusion, the infusion of histamine increased vWf-Ag level, and the inhibition of NO-synthase enhanced this effect, whereas it did not by itself elevate vWf-Ag level. Thus endogenously produced NO may dampen the regulated pathway of vWf secretion; it will be interesting to investigate whether endogenous NO production also inhibits vWf release caused by other stimulators.

[1]  K. Krejcy,et al.  Effects of estradiol on circulating P-selectin. , 1996, The Journal of clinical endocrinology and metabolism.

[2]  J. Kastner,et al.  Sex differences in concentrations of exhaled nitric oxide and plasma nitrate. , 1996, Life sciences.

[3]  F. Booth,et al.  An in vitro model for the study of acute release of von Willebrand factor from human endothelial cells , 1987, British journal of haematology.

[4]  J. Sixma,et al.  Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. , 1981, The Journal of laboratory and clinical medicine.

[5]  H. Eichler,et al.  Effects of desmopressin on circulating P‐selectin , 1996, British journal of haematology.

[6]  L. Raij,et al.  Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. , 1992, The Journal of clinical investigation.

[7]  M. Wolzt,et al.  Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. , 1997, The American journal of physiology.

[8]  J. White,et al.  Shortening of Bleeding Time by 1-Deamino-8-Arginine Vasopressin (DDAVP) in the Absence of Platelet von Willebrand Factor in Gray Platelet Syndrome , 1987, Thrombosis and Haemostasis.

[9]  L. Schmetterer,et al.  Role of nitric oxide in hemostatic system activation in vivo in humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[10]  C. Lowenstein,et al.  Nitric Oxide: A Physiologic Messenger , 1994, Annals of Internal Medicine.

[11]  C. Natanson,et al.  N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin , 1992, The Journal of experimental medicine.

[12]  J. Modig,et al.  Biochemical markers in a porcine model of adult respiratory distress syndrome induced by endotoxemia. , 1986, Resuscitation.

[13]  P. Vallance,et al.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock , 1991, The Lancet.

[14]  J. Rand,et al.  Subendothelial deposition of von Willebrand's factor requires the presence of endothelial cells. , 1982, The Journal of laboratory and clinical medicine.

[15]  J. Shelhamer,et al.  Effects of infused histamine: correlation of plasma histamine levels and symptoms. , 1982, The Journal of allergy and clinical immunology.

[16]  P. Mannucci,et al.  Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP) , 1992, British journal of haematology.

[17]  G. Striker,et al.  Binding and Release of Factor VIII/von Willebrand's Factor by Human Endothelial Cells , 1980, British journal of haematology.

[18]  J. Emeis,et al.  The Role of Cyclic Nucleotides in the Release of Tissue-Type Plasminogen Activator and von Willebrand Factor , 1993, Thrombosis and Haemostasis.

[19]  P. Ganz,et al.  Adenosine Nucleotides and Serotonin Stimulate von Wille-brand Factor Release from Cultured Human Endothelial Cells , 1994, Thrombosis and Haemostasis.

[20]  T. van der Poll,et al.  Tumor Necrosis Factor Induces von Willebrand Factor Release in Healthy Humans , 1992, Thrombosis and Haemostasis.

[21]  S. Moncada,et al.  Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? , 1991, The Lancet.

[22]  A. Schorer,et al.  Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells , 1987, British journal of haematology.

[23]  C. Rothschild,et al.  Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets. , 1987, The Journal of laboratory and clinical medicine.

[24]  P. Sims,et al.  Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. , 1989, The Journal of biological chemistry.

[25]  Esmon Nl,et al.  Factor IXa and von Willebrand factor modify the inactivation of factor VIII by activated protein C. , 1990 .

[26]  M. Wolzt,et al.  Nitric Oxide Synthase Inhibition in the Histamine Headache Model , 1997, Cephalalgia.

[27]  A. M. Lefer,et al.  Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. , 1994, Gastroenterology.

[28]  H. Eichler,et al.  Evidence against an effect of endothelin-1 on blood coagulation, fibrinolysis, and endothelial cell integrity in healthy men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[29]  H. Gralnick,et al.  von Willebrand factor release induced by endotoxin. , 1989, The Journal of laboratory and clinical medicine.

[30]  H. Weiss,et al.  Decreased adhesion of platelets to subendothelium in von Willebrand's disease. , 1974, The Journal of laboratory and clinical medicine.

[31]  P. Stolley,et al.  Sample size calculations for clinical pharmacology studies , 1986, Clinical pharmacology and therapeutics.

[32]  M. Wolzt,et al.  Systemic NO synthase inhibition blunts the chronotropic, but not the inotropic response to isoprenaline in man. , 1999, Nitric oxide : biology and chemistry.